EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Frontiers in CAR-T cell therapy for autoimmune diseases

Yan-Ruide Li, Zibai Lyu, Yuning Chen, Ying Fang, Lili Yang

Trends in Pharmacological Sciences · 2024-09 · 45 (9) · 839-857

DOI: 10.1016/j.tips.2024.07.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2024-09. Verfasst von Yan-Ruide Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: c…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has demonstrated significant success in treating cancers. The potential of CAR-T cells is now being explored in the context of autoimmune diseases. Recent clinical trials have shown sustained and profound elimination of autoreactive B cells by CAR-T cells, leading to promising autoimmune disease control with minimal safety concerns. These encouraging results have inspired further investigation into CAR-T cell applications for a broader range of autoimmune diseases and the development of advanced cell products with improved efficacy and safety. In this review, we discuss the mechanisms by which CAR-T cells target autoimmune conditions, summarize current preclinical models, and highlight ongoing clinical trials, including CAR-T therapy design, clinical outcomes, and challenges. Additionally, we discuss the limitations and future directions of CAR-T therapy in the treatment of autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsT-Lymphocytes

Stichwörter der Autor:innen

autoimmune diseaseautoreactive B cellsautoreactive T cellscell therapychimeric antigen receptor-engineered T (CAR-T) cellsimmunotherapy

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: charlie.li@ucla.edu.
  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095,…

Zitieren

APA

Li, Y. R., Lyu, Z., Chen, Y., Fang, Y., & Yang, L. (2024). Frontiers in CAR-T cell therapy for autoimmune diseases. Trends in Pharmacological Sciences, 45(9), 839-857. https://doi.org/10.1016/j.tips.2024.07.005

Vancouver

Li YR, Lyu Z, Chen Y, Fang Y, Yang L. Frontiers in CAR-T cell therapy for autoimmune diseases. Trends in Pharmacological Sciences. 2024;45(9):839-857. doi:10.1016/j.tips.2024.07.005

BibTeX
@article{Li2024,
  author = {Li, Yan-Ruide and Lyu, Zibai and Chen, Yuning and Fang, Ying and Yang, Lili},
  title = {Frontiers in CAR-T cell therapy for autoimmune diseases},
  journal = {Trends in Pharmacological Sciences},
  year = {2024},
  volume = {45},
  number = {9},
  pages = {839--857},
  doi = {10.1016/j.tips.2024.07.005}
}
Kostenlos starten →